| Estrogen and the risk of breast cancer M Clemons, P Goss New England Journal of Medicine 344 (4), 276-285, 2001 | 1602 | 2001 |
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non … KA Gelmon, M Tischkowitz, H Mackay, K Swenerton, A Robidoux, ... The lancet oncology 12 (9), 852-861, 2011 | 1327 | 2011 |
| Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design F Kassam, K Enright, R Dent, G Dranitsaris, J Myers, C Flynn, M Fralick, ... Clinical breast cancer 9 (1), 29-33, 2009 | 537 | 2009 |
| Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double … J Baselga, SA Im, H Iwata, J Cortés, M De Laurentiis, Z Jiang, CL Arteaga, ... The Lancet Oncology 18 (7), 904-916, 2017 | 527 | 2017 |
| PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer F Dupuy, S Tabariès, S Andrzejewski, Z Dong, J Blagih, MG Annis, ... Cell metabolism 22 (4), 577-589, 2015 | 522 | 2015 |
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer E Amir, N Miller, W Geddie, O Freedman, F Kassam, C Simmons, ... Journal of clinical oncology 30 (6), 587, 2012 | 519 | 2012 |
| Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer N Tchen, HG Juffs, FP Downie, QL Yi, H Hu, I Chemerynsky, M Clemons, ... Journal of clinical oncology 21 (22), 4175-4183, 2003 | 501 | 2003 |
| Perivascular M2 macrophages stimulate tumor relapse after chemotherapy R Hughes, BZ Qian, C Rowan, M Muthana, I Keklikoglou, OC Olson, ... Cancer research 75 (17), 3479-3491, 2015 | 465 | 2015 |
| Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the … I Judson, JA Radford, M Harris, JY Blay, Q van Hoesel, A Le Cesne, ... European Journal of Cancer 37 (7), 870-877, 2001 | 443 | 2001 |
| Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? C Simmons, N Miller, W Geddie, D Gianfelice, M Oldfield, G Dranitsaris, ... Annals of oncology 20 (9), 1499-1504, 2009 | 362 | 2009 |
| Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. SL Ellard, M Clemons, KA Gelmon, B Norris, H Kennecke, S Chia, ... Clin Oncol 27 (27), 4536-4541, 2009 | 332 | 2009 |
| Tamoxifen (‘Nolvadex’): a review: Antitumour treatment M Clemons, S Danson, A Howell Cancer treatment reviews 28 (4), 165-180, 2002 | 317 | 2002 |
| Insulin-lowering effects of metformin in women with early breast cancer PJ Goodwin, KI Pritchard, M Ennis, M Clemons, M Graham, IG Fantus Clinical breast cancer 8 (6), 501-505, 2008 | 305 | 2008 |
| Palliative Treatment of Painful Bone Metastases with MR Imaging–guided Focused Ultrasound1 D Gianfelice, C Gupta, W Kucharczyk, P Bret, D Havill, M Clemons Radiology 249 (1), 355-363, 2008 | 261 | 2008 |
| Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline S Dhesy-Thind, GG Fletcher, PS Blanchette, MJ Clemons, MS Dillmon, ... J Clin Oncol 35 (18), 2062-2081, 2017 | 254 | 2017 |
| A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for … HG Mar Fan, M Clemons, W Xu, I Chemerynsky, H Breunis, S Braganza, ... Supportive Care in Cancer 16, 577-583, 2008 | 223 | 2008 |
| Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer RA Dent, GJ Lindeman, M Clemons, H Wildiers, A Chan, NJ McCarthy, ... Breast cancer research 15, 1-8, 2013 | 221 | 2013 |
| The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting G Dranitsaris, A Molassiotis, M Clemons, E Roeland, L Schwartzberg, ... Annals of Oncology 28 (6), 1260-1267, 2017 | 204 | 2017 |
| Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer RJ Broom, PA Tang, C Simmons, L Bordeleau, AM Mulligan, ... Anticancer research 29 (5), 1557-1562, 2009 | 201 | 2009 |
| Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies E Amir, M Clemons, CA Purdie, N Miller, P Quinlan, W Geddie, ... Cancer treatment reviews 38 (6), 708-714, 2012 | 200 | 2012 |
Brian HuttonOttawa Hospital Research Institute, Senior ScientistVerified email at ohri.ca
